178 related articles for article (PubMed ID: 25057941)
1. Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF.
Stabile LP; Rothstein ME; Gubish CT; Cunningham DE; Lee N; Siegfried JM
J Thorac Oncol; 2014 Sep; 9(9):1285-93. PubMed ID: 25057941
[TBL] [Abstract][Full Text] [Related]
2. Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer.
Siegfried JM; Gubish CT; Rothstein ME; Queiroz de Oliveira PE; Stabile LP
Mol Pharmacol; 2007 Sep; 72(3):769-79. PubMed ID: 17550984
[TBL] [Abstract][Full Text] [Related]
3. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.
Navab R; Liu J; Seiden-Long I; Shih W; Li M; Bandarchi B; Chen Y; Lau D; Zu YF; Cescon D; Zhu CQ; Organ S; Ibrahimov E; Ohanessian D; Tsao MS
Neoplasia; 2009 Dec; 11(12):1292-300. PubMed ID: 20019837
[TBL] [Abstract][Full Text] [Related]
4. Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer.
Stabile LP; Lyker JS; Land SR; Dacic S; Zamboni BA; Siegfried JM
Carcinogenesis; 2006 Aug; 27(8):1547-55. PubMed ID: 16513678
[TBL] [Abstract][Full Text] [Related]
5. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
[No Abstract] [Full Text] [Related]
6. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis.
Stabile LP; Rothstein ME; Keohavong P; Jin J; Yin J; Land SR; Dacic S; Luong TM; Kim KJ; Dulak AM; Siegfried JM
Mol Cancer Ther; 2008 Jul; 7(7):1913-22. PubMed ID: 18645002
[TBL] [Abstract][Full Text] [Related]
7. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
Chen H; Lin C; Peng T; Hu C; Lu C; Li L; Wang Y; Han R; Feng M; Sun F; He Y
Cell Death Dis; 2020 Feb; 11(2):111. PubMed ID: 32041944
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.
Dohadwala M; Yang SC; Luo J; Sharma S; Batra RK; Huang M; Lin Y; Goodglick L; Krysan K; Fishbein MC; Hong L; Lai C; Cameron RB; Gemmill RM; Drabkin HA; Dubinett SM
Cancer Res; 2006 May; 66(10):5338-45. PubMed ID: 16707460
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-198 inhibition of HGF/c-MET signaling pathway overcomes resistance to radiotherapy and induces apoptosis in human non-small-cell lung cancer.
Zhu L; Xue F; Xu X; Xu J; Hu S; Liu S; Cui Y; Gao C
J Cell Biochem; 2018 Sep; 119(9):7873-7886. PubMed ID: 29943841
[TBL] [Abstract][Full Text] [Related]
10. hnRNPA2/B1 activates cyclooxygenase-2 and promotes tumor growth in human lung cancers.
Xuan Y; Wang J; Ban L; Lu JJ; Yi C; Li Z; Yu W; Li M; Xu T; Yang W; Tang Z; Tang R; Xiao X; Meng S; Chen Y; Liu Q; Huang W; Guo W; Cui X; Deng W
Mol Oncol; 2016 Apr; 10(4):610-24. PubMed ID: 26774881
[TBL] [Abstract][Full Text] [Related]
11. HGF/MET signaling promotes glioma growth via up-regulation of Cox-2 expression and PGE2 production.
Zhao Y; Sun Y; Zhang H; Liu X; Du W; Li Y; Zhang J; Chen L; Jiang C
Int J Clin Exp Pathol; 2015; 8(4):3719-26. PubMed ID: 26097553
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways.
Ogunwobi OO; Liu C
Clin Exp Metastasis; 2011 Dec; 28(8):721-31. PubMed ID: 21744257
[TBL] [Abstract][Full Text] [Related]
13. Endostar regulates EMT, migration and invasion of lung cancer cells through the HGF-Met pathway.
Shen Y; Chen Q; Li L
Mol Cell Probes; 2019 Jun; 45():57-64. PubMed ID: 31096000
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte growth factor produced in lung fibroblasts enhances non-small cell lung cancer cell survival and tumor progression.
Kanaji N; Yokohira M; Nakano-Narusawa Y; Watanabe N; Imaida K; Kadowaki N; Bandoh S
Respir Res; 2017 Jun; 18(1):118. PubMed ID: 28619066
[TBL] [Abstract][Full Text] [Related]
15. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.
Jiao D; Chen J; Li Y; Tang X; Wang J; Xu W; Song J; Li Y; Tao H; Chen Q
J Cell Mol Med; 2018 Jul; 22(7):3526-3536. PubMed ID: 29664235
[TBL] [Abstract][Full Text] [Related]
16. [Role of COX-2/PGE2/EP4 Axis-induced Macrophage Functional Activation
in NSCLC Development].
Zhao J; Zhu Q; Zhang Y; Li G; Zhang Y; Li F; Bian L
Zhongguo Fei Ai Za Zhi; 2024 Apr; 27(4):245-256. PubMed ID: 38769827
[TBL] [Abstract][Full Text] [Related]
17. Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
Li N; Li H; Su F; Li J; Ma X; Gong P
Int J Clin Exp Pathol; 2015; 8(8):9010-20. PubMed ID: 26464643
[TBL] [Abstract][Full Text] [Related]
18. [c-Met and HGF expression in non-small-cell lung carcinomas].
Korobko IV; Zinov'eva MV; Allakhverdiev AK; Zborovskaia IB; Svwrdlov ED
Mol Gen Mikrobiol Virusol; 2007; (2):18-21. PubMed ID: 17598453
[TBL] [Abstract][Full Text] [Related]
19. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
[TBL] [Abstract][Full Text] [Related]
20. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
